Enzo Biochem, Inc. (ENZ)
NYSE: ENZ · Real-Time Price · USD
0.4313
+0.0048 (1.13%)
At close: Mar 28, 2025, 4:00 PM
0.3493
-0.0820 (-19.01%)
Pre-market: Mar 31, 2025, 8:39 AM EDT
Enzo Biochem Revenue
Enzo Biochem had revenue of $7.33M in the quarter ending January 31, 2025, a decrease of -14.25%. This brings the company's revenue in the last twelve months to $29.09M, down -11.31% year-over-year. In the fiscal year ending July 31, 2024, Enzo Biochem had annual revenue of $31.91M with 2.72% growth.
Revenue (ttm)
$29.09M
Revenue Growth
-11.31%
P/S Ratio
0.77
Revenue / Employee
$213,926
Employees
136
Market Cap
22.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jul 31, 2024 | 31.91M | 846.00K | 2.72% |
Jul 31, 2023 | 31.06M | -1.58M | -4.85% |
Jul 31, 2022 | 32.64M | -85.09M | -72.27% |
Jul 31, 2021 | 117.73M | 41.71M | 54.87% |
Jul 31, 2020 | 76.02M | -5.15M | -6.34% |
Jul 31, 2019 | Pro | Pro | Pro |
Jul 31, 2018 | Pro | Pro | Pro |
Jul 31, 2017 | Pro | Pro | Pro |
Jul 31, 2016 | Pro | Pro | Pro |
Jul 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ENZ News
- 2 days ago - Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - GlobeNewsWire
- 13 days ago - Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results - GlobeNewsWire
- 2 months ago - Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules - GlobeNewsWire
- 3 months ago - Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update - GlobeNewsWire
- 5 months ago - Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend - GlobeNewsWire
- 8 months ago - Enzo Biochem to pay $4.5 mln for failing to safeguard patient data - Reuters
- 9 months ago - Enzo Biochem: Is This Time Finally Different? - Seeking Alpha
- 10 months ago - Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update - GlobeNewsWire